Education-centric outreach strengthens cognitive trust but underperforms when sponsor engagement is transactional and not ...
In today's ACT Brief, we examine the FDA's paused real-time complete response letter release policy, why programmatic patient ...
In this video interview, Gaynor Anders, chief delivery officer at Trialbee, explains why the industry's protocol-centric recruitment model has persisted so long and what a shift toward programmatic, ...
In a recent video interview with Applied Clinical Trials, Rob DiCicco, vice president of portfolio management at ...
In today's ACT Brief, we examine how FDA's single pivotal trial shift raises recruitment and retention stakes, why FSP should ...
In today's ACT Brief, we examine how local-first approaches can redesign clinical trial communication, quantitative evidence on risk-based quality management returns, and FDA approval of an oral ...
Functional unblinding is a central threat to validity; alternative controls, central blinded raters, blinding/expectancy questionnaires, and robust concordant endpoints are recommended to mitigate ...
Real-world RBQM performance data from 18 oncology trials were combined with Tufts CSDD oncology benchmarks to quantify trial- and program-level financial impact aligned with ICH E6(R3). Phase duration ...
In this video interview, Gaynor Anders, chief delivery officer at Trialbee, identifies organizational silos, siloed budgets, and a study-centric mindset as the biggest barriers to shifting from ...
Experience sampling captures real-time signals of site burden and operational friction at the moment they occur, providing earlier and more actionable insight than retrospective assessments and ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results